Notably, a decrease in CD4+ PD-1 levels after treatment showed a strong trend towards improved overall survival compared with cases showing increased levels (median survival not reached in the decreased group vs . 41.77 months in the increased group, P = 0.066).
← all excerpts
Distribution and clinical significance of peripheral blood lymphocyte PD-1 and PD-L1 in non-Hodgkin lymphoma: a retrospective study in Chinese patients.
1
—
—